AE37 peptide vaccination in prostate cancer: A 4-year immunological assessment updates on a phase i trial

Cancer Immunology, Immunotherapy

Volumn 62, Issue 10, 2013, Pages 1599-1608

  Perez, Sonia A ^a   Anastasopoulou, Eleftheria A ^a   Tzonis, Panagiotis ^a   Gouttefangeas, Cécile ^b   Kalbacher, Hubert ^b   Papamichail, Michail ^a   Baxevanis, Constantin N ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

AE37 vaccine; HER 2 neu; Immunological memory; Prostate cancer

Indexed keywords

AE36 PEPTIDE; AE37 PEPTIDE; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VACCINE;

ADULT; AGED; ARTICLE; CANCER IMMUNIZATION; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; CYTOKINE RELEASE; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSPOT ASSAY; ERYTHEMA; HUMAN; HUMAN CELL; IMMUNOLOGICAL MEMORY; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS FREE SURVIVAL; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PRURITUS; REGULATORY T LYMPHOCYTE; SKIN INDURATION; SKIN MANIFESTATION; TREATMENT OUTCOME; TUMOR IMMUNITY; ULCER;

ADULT; AGED; CANCER VACCINES; CELL GROWTH PROCESSES; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNIZATION, SECONDARY; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTOR, ERBB-2; T-LYMPHOCYTES;

EID: 84885859512     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1461-3     Document Type: Article

References (43)

1. Drake CG (2010) Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 10:580-593. doi: 10.1038/nri2817
2. Baxevanis CN, Voutsas IF, Gritzapis AD, Perez SA, Papamichail M (2010) HER-2/neu as a target for cancer vaccines. Immunotherapy 2:213-226. doi: 10.2217/imt.09.89
3. Carles J, Lloreta J, Salido M, Font A, Suarez M, Baena V, Nogue M, Domenech M, Fabregat X (2004) Her-2/neu expression in prostate cancer: a dynamic process? Clinical cancer research: an official journal of the American Association for Cancer Research 10:4742-4745. doi: 10.1158/1078-0432.CCR-04-0115
4. Shi Y, Brands FH, Chatterjee S, Feng AC, Groshen S, Schewe J, Lieskovsky G, Cote RJ (2001) Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol 166:1514-1519
5. Signoretti S, Montironi R, Manola J et al (2000) Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 92:1918-1925
6. Agus DB, Sweeney CJ, Morris MJ et al (2007) Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncolo Off J Am Soc Clin Oncol 25:675-681. doi: 10.1200/JCO.2006.07.0649
7. de Bono JS, Bellmunt J, Attard G et al (2007) Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol 25:257-262. doi: 10.1200/JCO.2006.07.0888
8. Salazar LG, Fikes J, Southwood S, Ishioka G, Knutson KL, Gooley TA, Schiffman K, Disis ML (2003) Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res Off J Am Assoc Cancer Res 9:5559-5565
9. Sotiriadou R, Perez SA, Gritzapis AD et al (2001) Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope. Br J Cancer 85:1527-1534. doi: 10.1054/bjoc.2001.2089
10. Gillogly ME, Kallinteris NL, Xu M, Gulfo JV, Humphreys RE, Murray JL (2004) Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer. Cancer immunol immunotherapy CII 53:490-496. doi: 10.1007/s00262-003-0463-y
11. Perez SA, von Hofe E, Kallinteris NL, Gritzapis AD, Peoples GE, Papamichail M, Baxevanis CN (2010) A new era in anticancer peptide vaccines. Cancer 116:2071-2080. doi: 10.1002/cncr.24988
12. Sotiriadou NN, Kallinteris NL, Gritzapis AD et al (2007) Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu + tumors. Cancer Immunol Immunother CII 56:601-613. doi: 10.1007/s00262-006-0213-z
13. Voutsas IF, Gritzapis AD, Mahaira LG, Salagianni M, von Hofe E, Kallinteris NL, Baxevanis CN (2007) Induction of potent CD4 + T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain. Int J Cancer 121:2031-2041. doi: 10.1002/ijc.22936
14. Perez SA, Kallinteris NL, Bisias S et al (2010) Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res 16:3495-3506. doi: 10.1158/1078-0432.CCR-10-0085
15. Sperner-Unterweger B, Neurauter G, Klieber M, Kurz K, Meraner V, Zeimet A, Fuchs D (2011) Enhanced tryptophan degradation in patients with ovarian carcinoma correlates with several serum soluble immune activation markers. Immunobiology 216:296-301. doi: 10.1016/j.imbio.2010.07.010
16. Widner B, Werner ER, Schennach H, Wachter H, Fuchs D (1997) Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem 43:2424-2426
17. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA J Am Med Assoc 281:1591-1597
18. Cheever MA, Higano CS (2011) PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res Off J Am Assoc Cancer Res 17:3520-3526. doi: 10.1158/1078-0432.CCR-10-3126
19. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ (2003) Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol 21:1232-1237
20. Sartor O (2011) Combination therapy: abiraterone prolongs survival in metastatic prostate cancer. Nat Rev Clin Oncol 8:515-516. doi: 10.1038/nrclinonc.2011.111
21. Knutson KL, Disis ML (2005) Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother CII 54:721-728. doi: 10.1007/s00262-004-0653-2
22. Melief CJ, van der Burg SH (2008) Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 8:351-360. doi: 10.1038/nrc2373
23. Ebert LM, MacRaild SE, Zanker D, Davis ID, Cebon J, Chen W (2012) A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma. PLoS ONE 7:e48424. doi: 10.1371/journal.pone. 0048424
24. Francois V, Ottaviani S, Renkvist N et al (2009) The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. Cancer Res 69:4335-4345. doi: 10.1158/0008-5472.CAN-08-3726
25. Welters MJ, Kenter GG, Piersma SJ et al (2008) Induction of tumor-specific CD4 + and CD8 + T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res Off J Am Assoc Cancer Res 14:178-187. doi: 10.1158/1078-0432.CCR-07-1880
26. Ayyoub M, Dojcinovic D, Pignon P, Raimbaud I, Schmidt J, Luescher I, Valmori D (2010) Monitoring of NY-ESO-1 specific CD4 + T cells using molecularly defined MHC class II/His-tag-peptide tetramers. Proc Natl Acad Sci USA 107:7437-7442. doi: 10.1073/pnas.1001322107
27. Derhovanessian E, Adams V, Hahnel K, Groeger A, Pandha H, Ward S, Pawelec G (2009) Pretreatment frequency of circulating IL-17 + CD4 + T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer 125:1372-1379. doi: 10.1002/ijc.24497
28. Jandus C, Bioley G, Dojcinovic D et al (2009) Tumor antigen-specific FOXP3 + CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts. Cancer Res 69:8085-8093. doi: 10.1158/0008-5472.CAN-09-2226
29. Gates JD, Clifton GT, Benavides LC et al (2010) Circulating regulatory T cells (CD4+ CD25+ FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide. Vaccine 28:7476-7482. doi: 10.1016/j.vaccine.2010.09.029
30. Angell H, Galon J (2013) From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol 25:261-267. doi: 10.1016/j.coi.2013.03.004
31. Fridman WH, Pages F, Sautes-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12:298-306. doi: 10.1038/nrc3245
32. Flammiger A, Weisbach L, Huland H et al (2013) High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. Eur J Cancer 49:1273-1279. doi: 10.1016/j.ejca.2012.11.035
33. Huen NY, Pang AL, Tucker JA et al (2013) Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer. Int J Cancer. doi: 10.1002/ijc.28026
34. Gulley JL, Arlen PM, Madan RA et al (2010) Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother CII 59:663-674. doi: 10.1007/s00262-009-0782-8
35. Degl'Innocenti E, Grioni M, Capuano G, Jachetti E, Freschi M, Bertilaccio MT, Hess-Michelini R, Doglioni C, Bellone M (2008) Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+ CD25+ regulatory T cells. Cancer Res 68:292-300. doi: 10.1158/0008-5472.CAN-07-2429
36. Wan YY, Flavell RA (2007) 'Yin-Yang' functions of transforming growth factor-beta and T regulatory cells in immune regulation. Immunol Rev 220:199-213. doi: 10.1111/j.1600-065X.2007.00565.x
37. Beriou G, Bradshaw EM, Lozano E et al (2010) TGF-beta induces IL-9 production from human Th17 cells. J Immunol 185:46-54. doi: 10.4049/jimmunol. 1000356
38. Lu Y, Hong S, Li H et al (2012) Th9 cells promote antitumor immune responses in vivo. J Clin Invest 122:4160-4171. doi: 10.1172/JCI65459
39. Smeltz RB, Chen J, Shevach EM (2005) Transforming growth factor-beta1 enhances the interferon-gamma-dependent, interleukin-12-independent pathway of T helper 1 cell differentiation. Immunology 114:484-492. doi: 10.1111/j.1365-2567.2005.02115.x
40. Rabinowitz KM, Wang Y, Chen EY et al (2013) Transforming growth factor beta signaling controls activities of human intestinal CD8(+)T suppressor cells. Gastroenterology 144(601-12):e1. doi: 10.1053/j.gastro.2012.12.001
41. Bierie B, Chung CH, Parker JS, Stover DG, Cheng N, Chytil A, Aakre M, Shyr Y, Moses HL (2009) Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest 119:1571-1582. doi: 10.1172/JCI37480
42. Godin-Ethier J, Pelletier S, Hanafi LA et al (2009) Human activated T lymphocytes modulate IDO expression in tumors through Th1/Th2 balance. J Immunol 183:7752-7760. doi: 10.4049/jimmunol.0901004
43. Riley JL (2013) Combination checkpoint blockade: taking melanoma immunotherapy to the next level. The New England journal of medicine. doi: 10.1056/NEJMe1305484